376 related articles for article (PubMed ID: 28231835)
1. Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12-month randomized controlled trial in patients with type 2 diabetes.
Dei Cas A; Spigoni V; Cito M; Aldigeri R; Ridolfi V; Marchesi E; Marina M; Derlindati E; Aloe R; Bonadonna RC; Zavaroni I
Cardiovasc Diabetol; 2017 Feb; 16(1):27. PubMed ID: 28231835
[TBL] [Abstract][Full Text] [Related]
2. Vildagliptin reduces plasma stromal cell-derived factor-1α in patients with type 2 diabetes compared with glimepiride.
Park KS; Kwak S; Cho YM; Park KS; Jang HC; Kim SY; Jung HS
J Diabetes Investig; 2017 Mar; 8(2):218-226. PubMed ID: 27575011
[TBL] [Abstract][Full Text] [Related]
3. Effects of vildagliptin compared with glibenclamide on glucose variability after a submaximal exercise test in patients with type 2 diabetes: study protocol for a randomized controlled trial, DIABEX VILDA.
Fofonka A; Ribeiro JP; Casali KR; Schaan BD
Trials; 2014 Nov; 15():424. PubMed ID: 25366037
[TBL] [Abstract][Full Text] [Related]
4. Effects of Sitagliptin on the Coronary Flow Reserve, Circulating Endothelial Progenitor Cells and Stromal Cell-derived Factor-1alpha.
Morishita T; Uzui H; Ikeda H; Amaya N; Kaseno K; Ishida K; Fukuoka Y; Tada H
Intern Med; 2019 Oct; 58(19):2773-2781. PubMed ID: 31243210
[TBL] [Abstract][Full Text] [Related]
5. Impact of treatment with glibenclamide or vildagliptin on glucose variability after aerobic exercise in type 2 diabetes: A randomized controlled trial.
Fofonka A; Bock PM; Casali KR; da Silveira AD; da Rosa FM; Berlanda G; Schaan BD
Diabetes Res Clin Pract; 2018 Sep; 143():184-193. PubMed ID: 29990565
[TBL] [Abstract][Full Text] [Related]
6. Effect of vildagliptin on hsCRP and arterial stiffness in patients with type 2 diabetes mellitus.
Zografou I; Sampanis C; Gkaliagkousi E; Iliadis F; Papageorgiou A; Doukelis P; Vogiatzis K; Douma S
Hormones (Athens); 2015; 14(1):118-25. PubMed ID: 25402372
[TBL] [Abstract][Full Text] [Related]
7. [Preclinical and clinical findings of the dipeptidyl peptidase-4 inhibitor vildagliptin].
Ito H; Wajima T; Yamaguchi M; Mimori N; Sekiguchi K
Nihon Yakurigaku Zasshi; 2010 Nov; 136(5):299-308. PubMed ID: 21079371
[No Abstract] [Full Text] [Related]
8. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.
Ahrén B; Pacini G; Tura A; Foley JE; Schweizer A
Horm Metab Res; 2007 Nov; 39(11):826-9. PubMed ID: 17992639
[TBL] [Abstract][Full Text] [Related]
9. Vildagliptin monotherapy. To be avoided, like other DPP-4 inhibitors.
Prescrire Int; 2013 May; 22(138):121. PubMed ID: 23819170
[No Abstract] [Full Text] [Related]
10. Effect of dipeptidyl peptidase-4 inhibitors on circulating tumor necrosis factor-α concentrations: A systematic review and meta-analysis of controlled trials.
Atkin SL; Katsiki N; Banach M; Mikhailidis DP; Pirro M; Sahebkar A
J Diabetes Complications; 2017 Sep; 31(9):1458-1464. PubMed ID: 28647512
[TBL] [Abstract][Full Text] [Related]
11. Beneficial effects of vildagliptin combined with miglitol on glucose tolerance and islet morphology in diet-controlled db/db mice.
Ishibashi K; Hara A; Fujitani Y; Uchida T; Komiya K; Tamaki M; Abe H; Ogihara T; Kanazawa A; Kawamori R; Watada H
Biochem Biophys Res Commun; 2013 Nov; 440(4):570-5. PubMed ID: 24103756
[TBL] [Abstract][Full Text] [Related]
12. The DPP-4 inhibitor vildagliptin: robust glycaemic control in type 2 diabetes and beyond.
Panina G
Diabetes Obes Metab; 2007 Sep; 9 Suppl 1():32-9. PubMed ID: 17877545
[TBL] [Abstract][Full Text] [Related]
13. Vildagliptin: a review of its use in type 2 diabetes mellitus.
Keating GM
Drugs; 2014 Apr; 74(5):587-610. PubMed ID: 24638989
[TBL] [Abstract][Full Text] [Related]
14. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.
Guerci B; Monnier L; Serusclat P; Petit C; Valensi P; Huet D; Raccah D; Colette C; Quéré S; Dejager S
Diabetes Metab; 2012 Oct; 38(4):359-66. PubMed ID: 22809630
[TBL] [Abstract][Full Text] [Related]
15. The dipeptidyl peptidase-4 inhibitor vildagliptin does not affect ex vivo cytokine response and lymphocyte function in patients with type 2 diabetes mellitus.
van Poppel PC; Gresnigt MS; Smits P; Netea MG; Tack CJ
Diabetes Res Clin Pract; 2014 Mar; 103(3):395-401. PubMed ID: 24485397
[TBL] [Abstract][Full Text] [Related]
16. Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients.
Cakirca M; Karatoprak C; Zorlu M; Kiskac M; Kanat M; Cikrikcioglu MA; Soysal P; Hursitoglu M; Camli AA; Erkoc R; Abdul-Ghani M
Drug Des Devel Ther; 2014; 8():239-43. PubMed ID: 24627624
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
Scheen AJ
Postgrad Med; 2013 May; 125(3):7-20. PubMed ID: 23748503
[TBL] [Abstract][Full Text] [Related]
18. Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience.
Foley JE; Jordan J
Vasc Health Risk Manag; 2010 Aug; 6():541-8. PubMed ID: 20730070
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
Guarino E; Nigi L; Patti A; Fondelli C; Dotta F
Expert Opin Pharmacother; 2012 Jun; 13(9):1377-84. PubMed ID: 22397507
[TBL] [Abstract][Full Text] [Related]
20. Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes.
Del Prato S
Int J Clin Pract Suppl; 2007 Aug; (154):38-48. PubMed ID: 17593276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
